Drugs / GLP-1-9,36
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01218633 Comparator | May 2011 → Jul 2012 | endocrine pancreas disorder | Adrian Vella | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLP-1-9,36 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01218633 ↗ |
| Known as | GLP-1-(9,36)amide | “Saline, GLP-1-(9,36)amide, or exendin-(9,39) at 30 pmol/kg/min (Ex 30) or 300 pmol/kg/min (Ex 300) were infused in random order on separate days.” PMID 23545708 ↗ Apr 2013 |
| Route | Other | “infused @ 1.2pmol/kg/min” NCT01218633 ↗ |